Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
2.430
-0.060 (-2.41%)
Jan 23, 2025, 12:19 PM EST - Market open
Pasithea Therapeutics Employees
Pasithea Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 7 or -46.67% compared to the previous year.
Employees
8
Change (1Y)
-7
Growth (1Y)
-46.67%
Revenue / Employee
n/a
Profits / Employee
-$1,971,885
Market Cap
3.08M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | -7 | -46.67% |
Dec 31, 2022 | 15 | 10 | 200.00% |
Dec 31, 2021 | 5 | 2 | 66.67% |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
KTTA News
- 9 days ago - Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Why Is Pasithea Therapeutics Stock Surging On Thursday? - Benzinga
- 4 months ago - Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire